U.S. markets close in 6 hours 27 minutes

Nemaura Medical Inc. (NMRD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4000+0.0126 (+3.25%)
As of 09:30AM EDT. Market open.

Nemaura Medical Inc.

57 West 57th Street
New York, NY 10019
United States
646 416 8000

IndustryMedical Devices
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Dr. Dewan Fazlul Hoque Chowdhury Ph.D.Chairman, CEO, Pres, Interim Principal Financial & Accounting Officer338.58kN/A1973
Dr. Arash GhadarChief Operating OfficerN/AN/A1977
Mr. Jay L. WarnerHead of U.S. Commercial OperationsN/AN/AN/A
Mr. Thomas Bendix MortensenHead of E.U. Commercial Operations & MarketingN/AN/AN/A
Ms. Samantha SandersGlobal Head of Digital ProgramsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Corporate Governance

Nemaura Medical Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.